New Treatment for Type 2 Diabetes Mellitus Using a Novel Bipyrazole Compound

• Published in: Cells (Basel, Switzerland) Vol. 12; no. 2; p. 267
• Main Authors: Alqudah, Abdelrahim, Qnais, Esam Y, Wedyan, Mohammed A, Altaber, Sara, Abudalo, Rawan, Gammoh, Omar, Alkhateeb, Hakam, Bataineh, Sajeda, Athamneh, Rabaa Y, Oqal, Muna, Abu-Safieh, Kayed, McClements, Lana
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 09-01-2023; MDPI
• Subjects: 2′,3,3,5′-tetramethyl-4′-nitro-2′H-1,3′-bipyrazole; Adipose tissue; AMP-Activated Protein Kinases; Animals; Body fat; Cholesterol; Diabetes; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Experimental - metabolism; Diabetes Mellitus, Type 2 - metabolism; Drug dosages; Glucose; Glucose transporter; High fat diet; Homeostasis; Inflammation; Insulin; Insulin resistance; Insulin Resistance - physiology; Interleukin 6; Kinases; Laboratory animals; Liver; Low density lipoprotein; Metabolism; Metformin; Metformin - pharmacology; Metformin - therapeutic use; Musculoskeletal system; Nitrogen; Oxidative stress; Plasma; Proteins; Rats; Skeletal muscle; Soleus muscle; Spectrum analysis; Streptozocin; United States > US; Spain; 2′,3,3,5′-tetramethyl-4′-nitro-2′H-1,3′-bipyrazole; inflammation; diabetes; insulin resistance; oxidative stress
• ISSN: 2073-4409; 2073-4409
• DOI: 10.3390/cells12020267

2',3,3,5'-Tetramethyl-4'-nitro-2'H-1,3'-bipyrazole (TMNB) is a novel bipyrazole compound with unknown therapeutic potential in diabetes mellitus. This study aims to investigate the anti-diabetic effects of TMNB in a high-fat diet and streptozotocin-(HFD/STZ)-induced rat model of type 2 diabetes mellitus (T2D). Rats were fed HFD, followed by a single low dose of STZ (40 mg/kg). HFD/STZ diabetic rats were treated orally with TMNB (10 mg/kg) or (200 mg/kg) metformin for 10 days before terminating the experiment and collecting plasma, soleus muscle, adipose tissue, and liver for further downstream analysis. TMNB reduced the elevated levels of serum glucose in diabetic rats compared to the vehicle control group (
0.001). TMNB abrogated the increase in serum insulin in the treated diabetic group compared to the vehicle control rats (
0.001). The homeostasis model assessment of insulin resistance (HOMA-IR) was decreased in the diabetic rats treated with TMNB compared to the vehicle controls. The skeletal muscle and adipose tissue protein contents of GLUT4 and AMPK were upregulated following treatment with TMNB (
0.001, < 0.01, respectively). TMNB was able to upregulate GLUT2 and AMPK protein expression in liver (
< 0.001, < 0.001, respectively). LDL, triglyceride, and cholesterol were reduced in diabetic rats treated with TMNB compared to the vehicle controls (
< 0.001, 0.01, respectively). TMNB reduced MDA and IL-6 levels (
< 0.001), and increased GSH level (
< 0.05) in diabetic rats compared to the vehicle controls. Conclusion: TMNB ameliorates insulin resistance, oxidative stress, and inflammation in a T2D model. TMNB could represent a promising therapeutic agent to treat T2D.